Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huzhou Aotesi Biochemical appears to have been a China-based manufacturer of silk-derived biochemical ingredients rather than a therapeutic drug developer. The company marketed silk protein, silk amino acids, sericin, silk fibroin, silk peptide, hydrolyzed silk powder, silkworm pupa powder, and related raw materials for use in food, health-care products, cosmetics, textiles, and potentially medicine-related applications. Public Chinese company registry information indicates the legal entity was renamed from Huzhou Aotesi Biochemical Co., Ltd. to Huzhou Aotesi Biotechnology Co., Ltd. and is now注销 (cancelled/deregistered), suggesting the company is no longer operating as an active registered business. The company described itself as ISO9001-certified, patent-holding, and based in Huzhou, Zhejiang, leveraging local silk resources and academic collaborations in China. There is no evidence of a therapeutic clinical pipeline or drug development program.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Huzhou Aotesi Biochemical.